167 related articles for article (PubMed ID: 26837766)
1. Mesenchymal Tumorigenesis Driven by TSC2 Haploinsufficiency Requires HMGA2 and Is Independent of mTOR Pathway Activation.
D'Armiento J; Shiomi T; Marks S; Geraghty P; Sankarasharma D; Chada K
Cancer Res; 2016 Feb; 76(4):844-54. PubMed ID: 26837766
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of HMGA2 in uterine leiomyoma associated with loss of TSC2 tumor suppressor gene function.
Hunter DS; Klotzbücher M; Kugoh H; Cai SL; Mullen JP; Manfioletti G; Fuhrman U; Walker CL
Cancer Res; 2002 Jul; 62(13):3766-72. PubMed ID: 12097287
[TBL] [Abstract][Full Text] [Related]
3. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.
Ma L; Chen Z; Erdjument-Bromage H; Tempst P; Pandolfi PP
Cell; 2005 Apr; 121(2):179-93. PubMed ID: 15851026
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of Tsc2 in Mesoderm-Derived Cells Causes Polycystic Kidney Lesions and Impairs Lung Alveolarization.
Ren S; Luo Y; Chen H; Warburton D; Lam HC; Wang LL; Chen P; Henske EP; Shi W
Am J Pathol; 2016 Dec; 186(12):3261-3272. PubMed ID: 27768862
[TBL] [Abstract][Full Text] [Related]
6. Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.
Wang F; Chen X; Li C; Sun Q; Chen Y; Wang Y; Peng H; Liu Z; Chen R; Liu K; Yan H; Ye BH; Kwiatkowski DJ; Zhang H
Oncogene; 2014 Aug; 33(34):4352-8. PubMed ID: 24077282
[TBL] [Abstract][Full Text] [Related]
7. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
8. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas.
Plank TL; Logginidou H; Klein-Szanto A; Henske EP
Mod Pathol; 1999 May; 12(5):539-45. PubMed ID: 10349994
[TBL] [Abstract][Full Text] [Related]
9. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibitor reverses autistic-like social deficit behaviours in adult rats with both Tsc2 haploinsufficiency and developmental status epilepticus.
Schneider M; de Vries PJ; Schönig K; Rößner V; Waltereit R
Eur Arch Psychiatry Clin Neurosci; 2017 Aug; 267(5):455-463. PubMed ID: 27263037
[TBL] [Abstract][Full Text] [Related]
11. mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis.
Li C; Chen H; Lan Z; He S; Chen R; Wang F; Liu Z; Li K; Cheng L; Liu Y; Sun K; Wan X; Chen X; Peng H; Li L; Zhang Y; Jing Y; Huang M; Wang Y; Wang Y; Jiang J; Zha X; Chen L; Zhang H
Cell Death Differ; 2019 Oct; 26(10):2015-2028. PubMed ID: 30760873
[TBL] [Abstract][Full Text] [Related]
12. Expression of tuberin and hamartin in tuberous sclerosis complex-associated and sporadic cortical dysplasia of Taylor's balloon cell type.
Grajkowska W; Kotulska K; Matyja E; Larysz-Brysz M; Mandera M; Roszkowski M; Domańska-Pakieła D; Lewik-Kowalik J; Jóźwiak S
Folia Neuropathol; 2008; 46(1):43-8. PubMed ID: 18368626
[TBL] [Abstract][Full Text] [Related]
13. Tuberous sclerosis in a 19-week fetus: immunohistochemical and molecular study of hamartin and tuberin.
Wei J; Li P; Chiriboga L; Mizuguchi M; Yee H; Miller DC; Greco MA
Pediatr Dev Pathol; 2002; 5(5):448-64. PubMed ID: 12202993
[TBL] [Abstract][Full Text] [Related]
14. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.
Ma L; Teruya-Feldstein J; Bonner P; Bernardi R; Franz DN; Witte D; Cordon-Cardo C; Pandolfi PP
Cancer Res; 2007 Aug; 67(15):7106-12. PubMed ID: 17671177
[TBL] [Abstract][Full Text] [Related]
15. Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2
Jones AT; Yang J; Narov K; Henske EP; Sampson JR; Shen MH
Neoplasia; 2019 Aug; 21(8):731-739. PubMed ID: 31207499
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
17. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development.
Li S; Takeuchi F; Wang JA; Fuller C; Pacheco-Rodriguez G; Moss J; Darling TN
J Exp Med; 2005 Sep; 202(5):617-24. PubMed ID: 16129702
[TBL] [Abstract][Full Text] [Related]
18. Tuberous sclerosis complex.
Islam MP; Roach ES
Handb Clin Neurol; 2015; 132():97-109. PubMed ID: 26564073
[TBL] [Abstract][Full Text] [Related]
19. PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.
Alves MM; Fuhler GM; Queiroz KC; Scholma J; Goorden S; Anink J; Spek CA; Hoogeveen-Westerveld M; Bruno MJ; Nellist M; Elgersma Y; Aronica E; Peppelenbosch MP
Sci Rep; 2015 Sep; 5():14534. PubMed ID: 26412398
[TBL] [Abstract][Full Text] [Related]
20. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
Kenerson H; Dundon TA; Yeung RS
Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
